Trial
NCT02387957
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ophthotech Corporation
Collaborators
—
Condition
Age-Related Macular Degeneration
Intervention
Fovista®
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-30